| Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. | |
| | |
MedLine Citation:
|
PMID: 19560812 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Thrombolytic therapy is an important treatment for thrombosis, a life-threatening condition in cardiovascular diseases. However, the traditional thrombolytic therapies have often been associated with the risk of severe bleeding. By conjugating urokinase with magnetic nanoparticles (MNPs), we have presented a strategy to control thrombolysis within a specific site. The covalent bioconjugate of urokinase and dextran-coated MNPs was synthesized and isolated. Thrombolysis by the conjugate was studied under a magnetic field in a rat arteriovenous shunt thrombosis model. The magnetic field was generated by two AlNiCo permanent magnets around the site of thrombus. The magnetic field enhanced the thrombolytic efficacy of the conjugate by 5-fold over urokinase with no reduction in plasma fibrinogen and little prolonged bleeding time. It suggested that thrombolysis had been specifically directed to the desired site by the magnetic carrier under the magnetic field. Additionally, the conjugate had a longer half-life than urokinase in circulation. |
| | |
Authors:
|
Feng Bi; Jing Zhang; Yijing Su; Yan-Chun Tang; Jian-Ning Liu |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-06-27 |
Journal Detail:
|
Title: Biomaterials Volume: 30 ISSN: 1878-5905 ISO Abbreviation: Biomaterials Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-08-04 Completed Date: 2009-10-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8100316 Medline TA: Biomaterials Country: England |
Other Details:
|
Languages: eng Pagination: 5125-30 Citation Subset: IM |
Affiliation:
|
Institute of Molecular Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Female Magnetics* Male Mice Mice, Inbred BALB C Nanoparticles / chemistry*, therapeutic use* Particle Size Rats Rats, Sprague-Dawley Thrombolytic Therapy* Urokinase-Type Plasminogen Activator / chemistry*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.73/Urokinase-Type Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Colonisation of fish and crabs of wave energy foundations and the effects of manufactured holes - a ...
Next Document: Functional PEG-peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cyto...